h 1356 has been researched along with bromodeoxyuridine in 1 studies
| Studies (h 1356) | Trials (h 1356) | Recent Studies (post-2010) (h 1356) | Studies (bromodeoxyuridine) | Trials (bromodeoxyuridine) | Recent Studies (post-2010) (bromodeoxyuridine) |
|---|---|---|---|---|---|
| 15 | 0 | 9 | 13,164 | 71 | 1,816 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grohé, C; van Eickels, M; Vetter, H | 1 |
1 other study(ies) available for h 1356 and bromodeoxyuridine
| Article | Year |
|---|---|
Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Benzimidazoles; Biphenyl Compounds; Bromodeoxyuridine; Cell Division; DNA-Binding Proteins; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Fibroblasts; Immediate-Early Proteins; Immunoblotting; Insulin-Like Growth Factor I; Isoquinolines; Myocardium; Oligopeptides; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred WKY; Receptor, IGF Type 1; Sp1 Transcription Factor; Tetrahydroisoquinolines; Tetrazoles; Time Factors; Transcription Factors | 2000 |